

TRIAL SCHEDULE

2021-2022

	Immune Monitoring (IM) - Accredited	Immune Monitoring (Alternative Technologies) (IM(AT)) - Accredited	CD34 Stem Cell Enumeration (CD34) - Accredited	Leukaemia Immunophenotyping (LI) - Accredited	Leukaemia Diagnostic Interpretation (LDI) - Accredited	Paroxysmal Nocturnal Haemoglobinuria (PNH) - Accredited	Low Level Leucocyte Enumeration (LLL) - Accredited	Minimal Residual Disease for ALL by Flow Cytometry (MRD-ALL) - Accredited	Pilot Minimal Residual Disease for CLL by Flow Cytometry (MRD-CLL) - Not Accredited	Pilot Minimal Residual Disease for AML by Flow Cytometry (MRD-AML) - Not Accredited	Pilot Minimal Residual Disease for Plasma Cell Myeloma by Flow Cytometry (MRD-PCM) - Not Accredited	Pilot Haematological Malignancy Bone Marrow Aspirate Assessment (HMBAA) - Not Accredited	Pilot Cerebrospinal Fluid (CSF) Immunophenotyping Programme - Not Accredited
Planned trial issues per financial year	6	6	6	6	6	6	6	4	4	4	3	4	3
APRIL 2021			X	X		X	X		X		X		
MAY 2021	X	X			X			X					X
JUNE 2021			X	X		X	X			X		X	
JULY 2021	X	X			X				X				
AUGUST 2021			X	X		X	X	X			X		
SEPTEMBER 2021	X	X			X					X		X	X
OCTOBER 2021			X	X		X	X		X				
NOVEMBER 2021	X	X			X			X					
DECEMBER 2021			X	X		X	X			X	X	X	
JANUARY 2022	X	X			X				X				X
FEBRUARY 2022			X	X			X	X					
MARCH 2022	X	X			X	X				X		X	

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments. Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte immunophenotyping.